Hemostasis and thrombosis in critically ill children

Seminars in Thrombosis and Hemostasis

Volumn 34, Issue 5, 2008, Pages 451-458

  Kenet, Gili ^a,b   Strauss, Tzipi ^a,b   Kaplinsky, Chaim ^b   Paret, Gideon ^b,c  

^a Safra Children's Hospital   (Israel)

^b SHEBA MEDICAL CENTER   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

Bleeding; DIC; Pediatric; RFVIIa; Thrombosis

Indexed keywords

ALPHA 2 MACROGLOBULIN; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; ANTITHROMBIN; APROTININ; BLOOD CLOTTING FACTOR; DESMOPRESSIN; FIBRINOGEN; FRESH FROZEN PLASMA; HEPARIN; HEPARIN COFACTOR II; LOW MOLECULAR WEIGHT HEPARIN; RECOMBINANT BLOOD CLOTTING FACTOR 7A; TRANEXAMIC ACID;

ANGIOGRAPHY; ANTICOAGULATION; ARTERY OCCLUSION; ARTERY THROMBOSIS; BLEEDING; BLOOD CLOT LYSIS; BLOOD CLOTTING DISORDER; BLOOD CLOTTING FACTOR 7 DEFICIENCY; BLOOD CLOTTING FACTOR DEFICIENCY; BLOOD TRANSFUSION; BLOOD TRANSFUSION REACTION; CARDIOPULMONARY BYPASS; CARDIOTOXICITY; CHILD; CHILD CARE; CHILDHOOD INJURY; CLINICAL FEATURE; CLINICAL PATHWAY; CLINICAL PROTOCOL; COLOR ULTRASOUND FLOWMETRY; COMPUTER ASSISTED TOMOGRAPHY; CONGENITAL HEART DISEASE; CRITICALLY ILL PATIENT; CYANOTIC HEART DISEASE; DIAGNOSTIC ACCURACY; DISEASE ACTIVITY; DISEASE COURSE; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG MECHANISM; ERYTHROCYTE CONCENTRATE; FULMINATING PURPURA; GENE MUTATION; GLANZMANN DISEASE; HEMOPHILIA A; HEMOPHILIA B; HEMOSTASIS; HUMAN; HYPERSENSITIVITY REACTION; INTENSIVE CARE; LIVER DISEASE; LUNG EMBOLISM; MORTALITY; NEPHROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCLUSIVE CEREBROVASCULAR DISEASE; OPEN HEART SURGERY; PATHOPHYSIOLOGY; PHLEBOGRAPHY; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SEPSIS; THROMBOCYTE DYSFUNCTION; THROMBOCYTOPENIA; THROMBOEMBOLISM; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; BLOOD COAGULATION DISORDERS; CHILD; CRITICAL ILLNESS; DISSEMINATED INTRAVASCULAR COAGULATION; FIBRINOLYTIC AGENTS; HEMORRHAGE; HEMOSTASIS; HUMANS; INTENSIVE CARE UNITS, PEDIATRIC; RISK FACTORS; THROMBOSIS;

EID: 55049111817     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0028-1092875     Document Type: Review

References (80)

1. Andrew M, David M, Adams M, et al. Venous thromboembolic complications (VTE) in children: first analyses of the Canadian Registry of VTE. Blood 1994;83:1251-1257
2. Monagle P, Adams M, Mahoney M, et al. Outcome of pediatric thromboembolic disease: a report from the Canadian Child-hood Thrombophilia Registry. Pediatr Res 2000; 47:763-766
3. Van Ommen CH, Heijboer H, Büller HR, Hirasing RA, Heijmans HSA, Peters M. Venous thromboembolism in childhood: a prospective two-year registry in The Netherlands. J Pediatr 2001;139:676-681
4. Tormene D, Gavasso S, Rossetto V, Simioni P. Thrombosis and thrombophilia in children: a systematic review. Semin Thromb Hemost 2006;32:724-728
5. Thornburg CA, Pipe S. Neonatal thromboembolic emergencies. Semin Fetal Neonatal Med 2006;11:198-206
6. Beardsley DS. Venous thromboembolism in the neonatal period. Semin Perinatol 2007;31:250-253
7. Williams MD, Chalmers EA, Gibson BE. The investigation and management of neonatal haemostasis and thrombosis. Br J Haematol 2002;119:295-309
8. Andrew M, Paes B, Milner R, et al. Development of the human coagulation system in the full-term infant. Blood 1987;70:165-172
9. McEwan A. Aspects of bleeding after cardiac surgery in children. Paediatr Anaesth 2007;17:1126-1133
10. Martinowitz U, Michaelson M. On behalf of the Israeli Multidisciplinary rFVIIa Task Force. Guidelines for the use of recombinant activated factor VII (rFVIIa) in uncontrolled bleeding: a report by the Israeli Multidisciplinary rFVIIa Task Force. J Thromb Haemost 2005;3:640-648
11. Blajchman MA, Vamvakas EC. The continuing risk of transfusion transmitted of infections. N Engl J Med 2006;355:1303-1305
12. Brohi K, Cohen MJ, Devenport RA. Acute coagulopathy of trauma: mechanism, identification and effect. Curr Opin Crit Care 2007;13:680-685
13. Bulutcu FS, Ozbek U, Polat B, Yalcin Y, Karaci AR, Bayindir O.Which may be effective to reduce blood loss after cardiac operations in cyanotic children: tranexamic acid, aprotinin or combination? Paediatr Anaesth 2005;15:41-46
14. Dietrich W, Ebell A, Busley R, Boulesteix AL. Aprotinin and anaphylaxis: analysis of 12,403 exposures to aprotinin in cardiac surgery. Ann Thorac Surg 2007;84:1144-1150
15. Mangano DT, Tudor IC, Dietzel C. The risk associated with aprotinin in cardiac surgery. N Engl J Med 2006;354:353-365
16. Khair K, Baker K, Mathias M, Burgess C, Leisner R. Intranasal desmopression (Octim): a safe and efficacious treatment option for children with bleeding disorders. Haemophilia 2007;13:548-551
17. Das P, Carcao M, Hitzler J. DDAVP-induced hyponatremia in young children. J Pediatr Hematol Oncol 2005;27:330-332
18. Guay J, DeMoerloose P, Lasne D. Minimizing perioperative blood loss and transfusions in children. Can J Anaesth 2006;53(6 Suppl):S59-S67
19. Kjalke M, Johannessen M, Hedner U. Effect of recombinant factor VIIa (NovoSeven) on thrombocytopenia-like conditions in vitro. Semin Hematol 2001;38:15-20
20. Galan AM, Tonda R, Pino M, et al. Increased local procoagulant action: a mechanism contributing to the favorable hemostatic effect of recombinant FVIIa in platelet disorder. Transfusion 2003;43:885-892
21. Lisman T, Mosnier LO, Lambert T, et al. Inhibition of fibrinolysis by recombinant factor VIIa in plasma from patients with severe hemophilia A. Blood 2002;99:175-179
22. Antovic JP, Antovic A. Does recombinant factor VIIa, apart from overall hemostasis, regulate TAFI dependent fibrinolysis? In vitro analysis using overall hemostasis potential (OHP) assay. Thromb Haemost 2003;90:620-627
23. Mathew P, Young G. Recombinant factor VIIa in paediatric bleeding disorders - a 2006 review. Haemophilia 2006;12:457-472
24. Levi M, Peters M, Buller HR. Efficacy and safety of recombinant factor VIIa for treatment of severe bleeding: a systematic review. Crit Care Med 2005;33:883-890
25. Kolban M, Balachowska-Kosciolek I, Chmielnicki M. Recombinant coagulation factor VIIa - a novel haemostatic agent in scoliosis surgery? Eur Spine J 2006;15:944-952
26. Heisel M, Nagib M, Madsen L, et al. Use of recombinant factor VIIa (rFVIIa) to control intraoperative bleeding in pediatric brain tumor patients. Pediatr Blood Cancer 2004;43:703-705
27. Almeida AM, Khair K, Hann I, Liesner R. The use of recombinant factor VIIa in children with inherited platelet function disorders. Br J Haematol 2003;121:477-481
28. Chuansumrit A, Tangnararatchakit K, Lektakul Y, et al. The use of recombinant activated factor VII for controlling life-threatening bleeding in dengue shock syndrome. Blood Coagul Fibrinolysis 2004;15:335-342
29. Pettersson M, Fischler B, Petrini P, et al. Recombinant FVIIa in children with liver disease. Thromb Res 2005;116:185-197
30. Greisen G, Andreasen RB. Recombinant factor VIIa in preterm neonates with prolonged prothrombin time. Blood Coagul Fibrinolysis 2003;14:117-120
31. Brown JB, Emerick KM, Brown DL, et al. Recombinant factor VIIa improves coagulopathy caused by liver failure. J Pediatr Gastroenterol Nutr 2003;37:268-272
32. Tobias JD, Groeper K, Berkenbosch JW. Preliminary experience with the use of recombinant factor VIIa to treat coagulation disturbances in pediatric patients. South Med J 2003;96:12-16
33. Markiewicz M, Kalicinski P, Kaminski A, et al. Acute coagulopathy after reperfusion of the liver graft in children: correction with recombinant activated factor VII. Transplant Proc 2003;35:2318-2319
34. Tobias JD, Simsic JM, Weinstein S, et al. Recombinant factor VIIa to control excessive bleeding following surgery for congenital heart disease in pediatric patients. J Intensive Care Med 2004;19:270-273
35. Pychynska-Pokorska M, Moll JJ, Krajewski , Jarosik P. The use of recombinant coagulation factor VIIa in uncontrolled postoperative bleeding in children undergoing cardiac surgery with cardiopulmonary bypass. Pediatr Crit Care Med 2004;5:246-250
36. Agarwal HS, Bennett JE, Churchwell KB, et al. Recombinant factor VII for postoperative bleeding in neonatal and pediatric cardiac surgery. Ann Thorac Surg 2007;84: 161-168
37. Veldman A, Neuhacuser C, Akintuerk H, Thul J, Schranz D, Michel-Behnke I. Recombinant factor VIIa in the treatment of persistant hemorrhage in pediatric patients on ECMO following surgery for congenital heart disease. Paediatr Anaesth 2007;17:1176-1181
38. Monroe DM, Roberts HR. Mechanism of action of high-dose factor VIIa: points of agreement and disagreement. Arterioscler Thromb Vasc Biol 2003;23:8-9
39. Hoffman M, Monroe DM. A cell-based model of hemostasis. Thromb Haemost 2001;85:958-965
40. Abshire TC. Dose optimization of recombinant factor VIIa for control of mild to moderate bleeds in inhibitor patients: improved efficacy with higher dosing. Semin Hematol 2004;41:3-7
41. O'Connell KA, Wood JJ, Wise RP, et al. Thromboembolic adverse events after use of recombinant human coagulation factor IIa. JAMA 2006;295:293-298
42. Mannucci PM, Levi M. Prevention and treatment of major blood loss. N Engl J Med 2007;356:2301-2311
43. Levi M, Ten Cate H. Dissemination intravascular coagulation. N Engl J Med 1999;341:586-592
44. Faust SN, Levin M, Harrison OB, et al. Dysfunction of endothelial protein C activation in severe meningococcal sepsis. N Engl J Med 2001;345:408-416
45. Levi M, De jonge E, Van der Poll T. Sepsis and disseminated intravascular coagulation. J Thromb Thrombolysis 2003;16:43-47
46. Levi M. Disseminated intravascular coagulation - What's new? Crit Care Clin 2005;21:449-467
47. Marti-Carvajal A, Salanti G, Cardona AF. Human recombinant activated protein for severe sepsis. Cochrane Database Syst Rev 2007;(3):CD004388
48. Kylat RI, Ohlsson A. A recombinant human activated protein C for severe sepsis in neonates. Cochrane Database Syst Rev 2006;(19):CD005385
49. Athale UH, Siciliano SA, Crowther M, Barr RD, Chan AK. Thromboembolism in children with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute protocols: effect of age and risk stratification of disease. Br J Haematol 2005;129:803-810
50. Glaser DW, Medeiros D, Rollins N, et al. Catheter-related thrombosis in children with cancer. J Pediatr 2001;138:255-259
51. Journeycake JM, Buchanan GR. Thrombotic complications of central venous catheters in children. Curr Opin Hematol 2003;10:369-374
52. Dubois J, Rypens F, Garel L, David M, Lacroix J, Gauvin F. Incidence of deep vein thrombosis related to peripherally inserted central catheters in children and adolescents. CMAJ 2007;177:1185-1190
53. Massicotte MP, Dix D, Monagle P, Adams M, Andrew M. Central venous catheter related thrombosis in children: analysis of the Canadian Registry of venous thromboembolic complications. J Pediatr 1998;133:770-776
54. Ruud E, Holmstrøm H, Hopp E, Wesenberg F. Central line-associated venous late effects in children without prior history of thrombosis. Acta Paediatr 2006;95:1060-1065
55. Hermansen MC, Hermansen MG. Intravascular catheter complications in the neonatal intensive care unit. Clin Perinatol 2005;32:141-156
56. Albisetti M, Schmugge M, Haas R, et al. Arterial thromboembolic complications in critically ill children. J Crit Care 2005;20:296-300
57. Monagle P, Newall F, Barnes C, et al. Arterial thromboembolic disease: a single-centre case series study. J Paediatr Child Health 2008;44:28-32
58. Kirkham F, Sebire G, Steinlin M, et al. Arterial ischaemic stroke in children. Review of the literature and strategies for future stroke studies. Thromb Haemost 2004;92:697-706
59. Goldenberg NA. Long-term outcomes of venous thrombosis in children. Curr Opin Hematol 2005;12:370-376
60. Nowak-Göttl U, Junker R, Kreuz W, et al. Childhood Thrombophilia Study Group. Risk of recurrent venous thrombosis in children with combined prothrombotic risk factors. Blood 2001;97:858-862
61. Goldenberg NA, Knapp-Clevenger R, Manco-Johnson MJ, Mountain States Regional Thrombophilia Group. Elevated plasma factor VIII and D-dimer levels as predictors of poor outcomes of thrombosis in children. N Engl J Med 2004;351:1081-1088
62. Young G. Diagnosis and treatment of thrombosis in children: general principles. Pediatr Blood Cancer 2006;46:540-546
63. Kotsakis A, Cook D, Griffith L, et al. Clinically important venous thromboembolism in pediatric critical care: a Canadian survery. J Crit Care 2005;20:373-380
64. Grandas OH, Klar M, Goldman MH, Filston HC. Deep venous thrombosis in the pediatric trauma population: an unusual event: report of three cases. Am Surg 2000;66:273-276
65. Athale UH, Chan AK. Thromboembolic complications in pediatric hematologic malignancies. Semin Thromb Hemost 2007;33:416-426
66. Kajimoto H, Nakazawa M, Murasaki K, et al. Increased thrombogenesity in patients with cyanotic congenital heart disease. Circ J 2007;71:948-953
67. Berkun Y, Padeh S, Barash J, et al. Antiphospholipid syndrome and recurrent thrombosis in children. Arthritis Rheum 2006;55:850-885
68. Dentali F, Gianni M, Agnelli G, Ageno W. Association between inherited thrombophilic abnormalities and central venous catheter thrombosis in patients with cancer: a meta-analysis. J Thromb Haemost 2008;6:70-75
69. Nowak-Gottl U, Kosch A, Schlegel N, et al. Thromboembolism in children. Curr Opin Hematol 2002;9:448-453
70. Marlar RA, Neumann A. Neonatal purpura fulminans due to homozygous protein C or protein S deficiencies. Semin Thromb Hemost 1990;16:299-309
71. Zimbelman J, Lefkowitz J, Schaeffer C, et al. Unusual complications of warfarin therapy: skin necrosis and priapism. J Pediatr 2000;137:266-268
72. Pescatore SL. Clinical management of protein C deficiency. Expert Opin Pharmacother 2001;2:431-439
73. Monagle P, Michelson AD, Bovill E, Andrew M. Antithrombotic therapy in children. Chest 2001;119:344S-370S
74. Shah PS, Shah N. Heparin-bonded catheters for prolonging the patency of central venous catheters in children. Cochrane Database Syst Rev 2007;(4):CD005983
75. Nowak-Göttl U, Bidingmayer C, Krümpel A, et al. Pharmacokinetics, efficacy, and safety of LMWHs in venous thrombosis and stroke in neonates, infants and children. Br J Pharmacol 2008;153:1120-1127
76. Robinson A, Fellows KE, Bridges ND, Rome JJ. Effectiveness of pharmacomechanical thrombolysis in infants and children. Am J Cardiol 2001;87:496-499
77. Manco-Johnson MJ, Grabowski EF, Hellgreen M, et al. Recommendations for tPA thrombolysis in children. On behalf of the Scientific Subcommittee on Perinatal and Pediatric Thrombosis of the Scientific and standardization Committee of the International Society of Thrombosis and Haemostasis. Thromb Haemost 2002;88:157-158
78. Goldenberg NA, Durham JD, Knapp-Clevenger R, Manco-Johnson MJ. A thrombolytic regimen for high-risk deep venous thrombosis may substantially reduce the risk of postthrombotic syndrome in children. Blood 2007;110:45-53
79. Belvis R. Thrombolysis for acute stroke in pediatrics. Stroke 2007;38:1722-1723
80. Young G, Tarantino MD, Whorley J. Pilot dose-finding and safety study of bivalirudin in infants <6 months of age with thrombosis. J Thromb Haemost 2007;5:1654-1659